Long-term outcomes in dogs with sinonasal aspergillosis treated with intranasal infusions of enilconazole.
Long-term outcomes (mean 38+/-17 months) were evaluated in 27 dogs with sinonasal aspergillosis after successful medical treatment using intranasal infusions of 1% or 2% enilconazole (1%, n=15; 2%, n=12). Long-term outcomes with both treatment protocols were good, with half of the dogs being asymptomatic throughout the follow-up period. The remaining dogs showed mild clinical signs compatible with chronic rhinitis/sinusitis. These clinical signs were interpreted as chronic lymphoplasmacytic rhinitis/sinusitis and episodes of bacterial rather than fungal infection. Three dogs had confirmed reinfection or relapse 2 to 36 months after clinical resolution.
Schuller
Simone
S
Department of Clinical Sciences, ULG-Faculty of Veterinary Medicine, Bld de Colonster, 20-B44, Sart Tilman, 4000 Liège, Belgium.
Clercx
Cecile
C
D000287:Administration, Topical; D000818:Animals; D001228:Aspergillosis / Q000188:drug therapy / Q000662:veterinary*; D004283:Dog Diseases / Q000188:drug therapy* / Q000382:microbiology; D004285:Dogs; D004724:Endoscopy / Q000662:veterinary; D005260:Female; D005659:Fungicides, Industrial / Q000008:administration & dosage / Q000627:therapeutic use*; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D010254:Paranasal Sinus Diseases / Q000188:drug therapy / Q000382:microbiology / Q000662:veterinary*; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
D005659:Fungicides, Industrial; D007093:Imidazoles; C017435:enilconazole